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Abstract:Melittin, the major active peptide of honeybee venom (BV), has potential for use in adjuvant
immunotherapy. The immune system response to different stimuli depends on the secretion of different
metabolites from macrophages. One potent stimulus is lipopolysaccharide (LPS), a component
isolated from gram-negative bacteria, which induces the secretion of pro-inflammatory cytokines in
macrophage cell cultures. This secretion is amplified when LPS is combined with melittin. In the
present study, pure melittin was isolated from whole BV by flash chromatography to obtain pure
melittin. The ability of melittin to enhance the release of tumour necrosis factor-α (TNF-α), Interleukin
(IL-1β, IL-6, and IL-10) cytokines from amacrophage cell line (THP-1) was then assessed. The response
to melittin and LPS, applied alone or in combination, was characterised by metabolic profiling, and the
metabolomics results were used to evaluate the potential of melittin as an immune adjuvant therapy.
The addition of melittin enhanced the release of inflammatory cytokines induced by LPS. Effective
chromatographic separation ofmetabolites was obtained by liquid chromatography-mass spectrometry
(LC-MS) using a ZIC-pHILIC column and an ACE C4 column. The levels of 108 polar and non-polar
metabolites were significantly changed (p < 0.05) following cell activation by the combination of LPS
and melittin when compared to untreated control cells. Overall, the findings of this study suggested
that melittin might have a potential application as a vaccine adjuvant.
Keywords: melittin; pro- and anti-inflammatory cytokines; LPS stimulation; THP-1 cells; PMA
differentiated; macrophages; adjuvant vaccine
1. Introduction
Correct recognition of inflammatory signals in the body is vital to avoid the risk of autoimmune
and chronic inflammatory diseases. Many of these signals arise from macrophages, and thus
determination and investigation of the composition of local tissue microenvironments (e.g., metabolites,
cytokines, and inflammatory signals) can be performed in order to understand the metabolic behaviour
of macrophages following their activation [1]. Inflammation is a primary process that is triggered as
a protective response to any stimulus of the innate immune system, such as injuries or infections, which
pose a real threat to normal cell biology [2]. Inflammation can be initiated by first-line macrophage
cells and dendritic cells to protect the body from external pathogens. Pathogen-associated molecular
patterns (PAMPs) present in the invaders are recognised by specific receptors, the pattern recognition
receptors (PRRs), present on the surface of these cells. PRRs play a crucial role in the stimulation of the
innate immune system and the resulting signalling cascade [3]. The pathogen is targeted by the release
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of antimicrobial mediators, while further immune cells are recruited to the infection site by chemokine
secretion. These chemokines include pro-inflammatory cytokines released by T and B lymphocytes to
induce further inflammation and activate the adaptive immune response [4]. Several classes of PRRs
have been characterised and investigated, including the toll-like receptors (TLRs) which are expressed
on plasma membranes and activated by lipopolysaccharides (LPSs) from gram-negative bacteria [5].
The biosynthesis and/or depletion of cellular metabolites in response to pathogen invasion results
in rapid alteration in the cellular metabolome [6]. Upon activation, innate immune cells undergo
metabolic changes that can be described as similar to those that occur in cancer cells (Warburg effect) [4].
In the presence of oxygen, the metabolic profile of a tumour shows an increase in glycolysis under
normoxic conditions, so that metabolism is shifted to produce lactic acid from pyruvate instead of
the acetyl-CoA needed to feed the tricarboxylic acid (TCA) cycle and oxidative phosphorylation
(OXPHOS) to generate adenosine triphosphate (ATP) [7]. The consumption of glucose and oxygen
has long been known to increase in response to activation of TLR4 in innate immune cells by LPS.
However, this oxygen consumption also reflects an increased generation of reactive oxygen species
(ROS) [8]. Some enzymes in the glycolysis pathway, such as hexokinase and glucose-6-phosphate
dehydrogenase, also show increased expression, leading to a further increase in glycolytic activities [9].
Inflammatory macrophages, when induced with LPS to release pro-inflammatory cytokines, therefore
show a decreased utilisation of both the TCA cycle and OXPHOS metabolites as a consequence of
this increase in glycolysis (glucose to lactate) to compensate the lack of ATP production via oxidative
phosphorylation [10,11]. Interestingly, the cell metabolite adaptation occurs even in the presence
of “aerobic glycolysis” [12]. This metabolic adaptation works as a survival response that serves to
maintain mitochondrial membrane potential and cell integrity [13].
Understanding the process of macrophage activation by LPS is important for the identification
of suitable immune stimulators, and these metabolic shifts could therefore be useful in this type of
research. Macrophages stimulated by LPS generally show one or more of the following main metabolic
shifts [4], which result in the expression of specific sets of genes. The first is a highly increased
expression of inducible nitric oxide synthase (iNOS), which leads to the generation of citrulline
and nitric oxide (NO) [14]. The latter results in the process of iron–sulphur protein nitrosylation in
the electron transport chain which decreases mitochondrial respiration by inhibiting OXPHOS [15].
The second shift occurs due to activation of the glycolysis pathway in macrophages through activation
of hypoxia inducible factor-1α (HIF-1α) [4], which then promotes the expression of its target genes,
such as GLUT1 [16] and lactate dehydrogenase [17]. The increase in HIF-1α expression can be achieved
by the activation of the mammalian target of rapamycin (mTOR), which is promoted by the translation
of mRNAs with 5’TOP (5’-terminal oligopyrimidine) [18]. The third shift arises by an increase in the
expression of phosphofructokinase-2 (PFK2) isoforms (i.e., u-PFK2), which causes an increase in the
level of fructose-2,6-bisphosphate (F-2,6-BP) and activates the 6-phosphofructo-1-kinase glycolytic
enzyme [19]. The fourth shift is due to inactivation of adenosine monophosphate-activated protein
kinase (AMPK) in macrophages, which causes a decrease in fatty acid β-oxidation and mitochondrial
metabolism. These actions boost the biosynthesis of inflammatory mediators and inhibit the catabolic
pathways of the AMPK enzyme [20].
One promising immune modulator is melittin, the major lytic peptide of bee venom (BV). Many
compounds have been isolated from BV, but melittin is the major component, accounting for as much
as 50–60% of dried whole BV. Other components include peptides and proteins such as apamine,
mast cell degranulating (MCD) peptide, secapin, adolapin, phospholipase A2, and hyaluronidase [21].
The enzymes, though present in relatively small amounts, are notable for being powerful allergens,
and in some cases (e.g., phospholipase A2) synergise directly with melittin in its lytic action. Melittin
is a 26-mer peptide with a characteristic sequence that provides the peptide chain with amphiphilic
detergent-like properties and a high positive charge. It can self-assemble into tetramers depending on
conditions [22,23] and has attracted considerable attention for its potential for selective destruction of
cancer cells [24,25].
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Melittin shows antiviral, antifungal, antibacterial, and anti-parasitic properties according to
several studies and has been proposed to act at cell membrane level [26–28]. However, previous
results regarding the effect of melittin on the immune system are inconsistent, indicating a need to
perform more investigations. For example, melittin was characterised as an inhibitor of the release of
prostaglandin E2 (PGE2) and nitric oxide (NO) from LPS-treated RAW 264.7 cells and synoviocytes,
which showed a dose dependent inhibition of LPS-induced Cyclooxygenase enzyme (COX-2) and
iNOS when treated with BV and melittin [29]. Similarly, melittin treatment of Propionibacterium
acnes (P. acnes)-induced THP-1 monocytes significantly inhibited production of the pro-inflammatory
cytokines TNF-α and IL-1β and cleavage of caspase-2 and -8 [30]. The mechanism of this inhibition
was believed to occur in one of two possible ways: by the inhibition of Nuclear factor-kappa B
(NF-κb) activation by melittin through interaction with the p50 subunit or by phosphorylation of IκB
subunit [29,31]. The NF-κB transcription factor is crucial in inflammation as the expression of most
of the pro-inflammatory genes rely on activation by this factor [32]. Anti-inflammatory activity of
melittin and its interaction with LPS was referred to its amino acid sequences, particularly hydrophobic
leucine zipper sequence [33]. By contrast, Stuhlmeier reported that neither BV nor melittin blocked
IL-1β induced activation of NF-κB or had any effect on IκB phosphorylation or degradation using
electrophoretic mobility shift (EMSA) assay in several cell types [21]. Moreover, BV andmelittin, even at
high concentrations, did not compete for NF-κB-p50-DNA binding or show any interactions. However,
the mRNA levels of many types of pro-inflammatory genes and COX-2 protein were significantly
elevated following exposure to BV and melittin. In addition, oxygen radicals were released in large
amounts in a dose-dependentmanner in response to BV treatment [21]. Another study, which examined
the effects of BV and its isolated compounds on the production of pro-inflammatory cytokines in
phorbol 12-myristate 13-acetate (PMA)-differentiated U937 cells, showed that the expressions of TNF-α,
IL-1β, and IL-6 cytokines increased in response to melittin and LPS co-stimulation when compared to
LPS stimulation alone [34].
Melittin can also be used as an adsorption enhancer in Caco-2 cells [35], indicating its possible
usefulness as an adjuvant for nasal administrations [36]. In addition, melittin has been reported to
enhance antibody titres when co-administered with tetanus and diphtheria toxoid, which facilitated
the longevity of the immune response when compared to antigen administration alone [37]. Based on
these observations, melittin shows significant effects on cell inflammatory signalling, which support
the use of melittin as an efficient immunomodulatory agent rather than for pro-inflammatory cytokine
neutralisation. More investigations are needed to assess the differences in the mechanism of action of
LPS and melittin, and the synergy between melittin and LPS in triggering the immune system. One
possible strategy would be to evaluate the metabolic changes that occur in macrophages in response to
melittin and LPS when administered singly or in combination.
Metabolomics is one way to provide a quantitative identification of endogenous and exogenous
cell metabolites to reveal the relative pathway relationships between metabolites and observed
physiological and/or pathological alterations. Metabolomics studies are now providing a number of
advantages for determining health status, such as providing predictive powers and diagnosing the
disease state, revealing biological markers for drug responses, and defining the links to genetic
variants [38]. Most metabolomics studies use untargeted metabolomic profiling for analysis of
small molecule metabolites and are typically performed by nuclear magnetic resonance (NMR)
spectroscopy and mass spectrometry (MS), highly sensitive and accurate instruments. The coupling of
MS to high performance liquid chromatography (HPLC) allows the separation and identification of
thousands of metabolites in a single biological sample. Many research studies are now focusing
on using metabolomics in diverse areas [24,39,40], including the study of inflammatory related
metabolites [41,42]. For instance, Traves et al. characterised the metabolic network flux and changes
and its relation to signal transduction in LPS-activated macrophages [43].
Effects on many metabolites have been described in observations of innate immune cell
metabolism. Understanding the interface between these immune cells and their metabolism could
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therefore provide novel tools for manipulating cellular activities. For example, the production
of pro-inflammatory cytokines contribute to systemic inflammation [44]. Similarly, the loss of
cellular mass promoted by TNF-α has been characterised in cachexia, demonstrating a link between
inflammation and metabolism [45]. The quality and the benefit-to-risk ratio of immunisations could
be improved by identification of specific metabolites; for example, metabolic profiling of patients
pre- and post-smallpox vaccination was able to distinguish patient clinical samples with myocarditis
and asymptomatic elevation of troponins, suggesting the potential for identification of biomarkers
related to adverse vaccine reactions [46,47]. Moreover, understanding alterations in metabolomics
pathways due to vaccination could help to improve new target vaccine designs (adjuvants, antigens
and nanoparticle carrier systems), as reported by Gray et al., who used Ultra high performance liquid
chromatography-mass spectrometry (UPLC-MS) metabolomic profiling of plasma in calves following
vaccination to determine the immune-correlated metabolite characteristics of immune responses [48].
The current knowledge of immune metabolism has been widely advanced by improvements in
metabolomics-based technologies.
Major efforts are now focused on the identification and innovation of new pharmacological
compounds to enhance immune responses. The aim of the current study was to use enzyme-linked
immunosorbent assay (ELISA) to evaluate the changes in the production of pro- and anti-inflammatory
cytokines (TNF-α, IL-1β, IL-6, and IL-10) following the administration ofmelittin to PMA-differentiated
THP-1 cells. A secondary aimwas to examine the changes in themetabolic profile of THP-1macrophage
cells in response to melittin in the presence and absence of LPSs. This was performed using an
LC-MS-based metabolomics approach employing ZIC-pHILIC and ACE C4 columns for polar and
non-polar metabolites, respectively. The determination of the metabolic changes in response to melittin
in stimulated monocyte-derived macrophages cells could be of value for many vaccine applications
and the main objective of the present study was to evaluate this potential.
2. Materials and Methods
2.1. Sample Isolation and Preparation
Melittin was isolated and purified from BV (supplied lyophilised by Beesen Co. Ltd., Dae Jeon,
Korea) using reversed phase medium pressure liquid chromatography (MPLC) on a Reveleris® iES
flash chromatography system (Grace Davison Discovery Sciences, Carnforth, UK) with dual UV
(λ = 220/280 nm) and evaporative light scattering detection (ELSD). This was performed using the
same method previously described [49]. The resultant BV fractions were freeze-dried and stored at
−20 ◦C until required for the assays.
2.2. Cell Culture and Differentiation
The THP-1 cell line was obtained from American Type Culture Collection-ATCC® (Porton Down,
Salisbury, UK) and maintained at a 1 × 105 cell/mL seeding density in RPMI 1640 (Thermos Fisher
Scientific, Loughborough, UK) containing 10% (v/v) foetal calf serum (FCS) (Life Tech, Paisley, UK),
2 mmol/L L-glutamine (LifeTech, Paisley, UK), and 100 IU/100 µg/mL penicillin/streptomycin (Life
Tech, Paisley, UK). Cells were sub-cultured using fresh media every 2–4 days and maintained in an
incubator (37 ◦C, 5% CO2, 100% humidity). THP-1 cells were differentiated using PMA (Sigma-Aldrich,
Dorest, UK) at a final concentration of 60 ng/mL and incubated for 48 h. THP-1 cell differentiation was
enhanced by removing the PMA-containing media and adding fresh media for a further 24 h. Cells
were checked under a light microscope for the evidence of differentiation.
2.3. Cell Viability Assay
The THP-1 cells were seeded at a density of 1 × 105/well in 96-well plates and incubated for
24 h at 37 ◦C in a humidified atmosphere of 5% CO2. After 24 h, the cells were treated with different
concentrations of melittin (0.39–100 µg/mL) and incubated for a further 24 h. Untreated control cells
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and mediumwere added to the plates and dimethyl sulphoxide (DMSO) was used as a positive control.
Resazurin salt solution (0.1 mg/mL) was added at a final concentration of 10% (v/v) and the plates were
incubated for a further 24 h. Fluorescence readings were taken using a SpectraMax M5 plate reader
(Molecular Devices, Sunnyvale, CA, USA) at λEx of 560 nm and λEm of 590 nm. After background
correction, cell viability for each concentration was calculated relative to the mean value of negative
control (n = 3). GraphPad Prism for Windows (version 5.00, GraphPad Software, San Diego, CA, USA)
was used to obtain dose–response curves and mean inhibitory concentration (IC50) values.
2.4. Cytokine Production
After 48 h of differentiation using PMA (60 ng/mL) in 24-well plates, the media were aspirated,
and the cells were incubated for a further 24 h in PMA-free medium. At day 4, the cells were incubated
with final concentrations of melittin (0.5 and 1 µg/mL) with and without LPS (Sigma-Aldrich) (0.5 and
1 µg/mL) for an additional 24 h. Conditioned medium was collected and frozen until required for
ELISA (n = 3).
2.5. Enzyme-Linked Immunosorbent Assay (ELISA)
ELISA Ready-Set-Go kits were purchased from Thermo Fisher Scientific (Loughborough, UK).
The assays were performed according to the manufacturer’s instructions to quantify the release of
inflammatory cytokines (TNF-α, IL-1β, IL-6, and IL-10). The reaction was stopped using acid solution
(2 N sulphuric acid). The plates were read using a SpectraMax M5 plate reader (Molecular Devices,
Sunnyvale, CA, USA) at 560 nm and the absorbance values were corrected by subtracting readings
taken at 570 nm.
2.6. Metabolite Extraction
The PMA-differentiated THP-1 cells were grown for 48 h in 6-well plates seeded at a density
of 4.5 × 105/well (n = 6). The medium was aspirated and replaced with fresh medium for a further
24 h, and then the cells were incubated with LPS, melittin, or a combination of LPS and melittin for
an additional 24 h. The final concentrations of LPS and melittin were 0.5 and 1 µg/mL, respectively.
After 24 h, the medium was aspirated, and the cells were washed with 3 mL of phosphate-buffered
saline (PBS) (Sigma-Aldrich) at 37 ◦C. The cells were extracted (1 mL per 1 × 106 cells) by ice
cold extraction solution (methanol:acetonitrile:water, 50:30:20 (v/v), containing 5 µg/mL of internal
standard 13C2 glycine (Sigma-Aldrich, Poole, UK)). The cells were scraped, and cell lysates were
mixed in a Thermomixer (12 min, 4 ◦C), and then centrifuged for 15 min at 0 ◦C (13,500 r.p.m.).
The supernatants were collected and stored at −80 ◦C until required for LC-MS analysis. The stability
and reproducibility of the analytical method was ensured by injecting authentic standard metabolite
mixtures and quality control (QC) samples throughout the runs. The analytical standards were
prepared by adding 10 µg/mL final concentration of each metabolite standard [50] containing 13C2
glycine, distributed into seven different standard solutions. The pooled quality control samples were
prepared by pipetting 20 µL from each of the samples and mixing them together before transferring
them into a HPLC vial. A mixture of fatty acid standards was prepared from a mixture of 37 fatty acid
methyl ester standards supplied by Sigma Aldrich (Supelco 37 component FAME Mix) by hydrolysis
with 1 M methanolic KOH followed by extraction into hexane.
2.7. LC-MS Conditions
An Accela HPLC system interfaced to an Exactive Orbitrap mass spectrometer (Thermo Fisher
Scientific, Bremen, Germany) was used for the liquid chromatographic separations. ZIC-pHILIC
(150 × 4.6 mm, 5 µm) and ACE C4 (150 × 3.0 mm, 3 µm) HPLC columns supplied by HiChrom
(Reading, UK) were used. Samples were run on LC-MS under the following conditions: the
ZIC-pHILIC mobile phase consisted of 20 mM ammonium carbonate in HPLC-grade water (A) and
acetonitrile (B); the solvent gradient used was 80% B (0 min), 20% (30 min), 8% (31–36 min), and 80%
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(37–45 min) at a flow rate of 0.3 mL/min. For the ACE C4 column, the mobile phase was 1 mM acetic
acid in water (A) and 1 mM acetic acid in acetonitrile (B). The solvent gradient used was 40% B (0 min),
100% (30–36 min) and 40% (37–41 min) at a flow rate of 0.4 mL/min. The nitrogen sheath and auxiliary
gas flow rates were maintained at 50 and 17 arbitrary units. The electrospray ionisation (ESI) interface
was employed in a positive/negative dual polarity mode, with a spray voltage of 4.5 kV for positive
mode and 4.0 kV for negative mode, while the ion transfer capillary temperature was set at 275 ◦C.
Full scan data were obtained in the mass-to-charge ratio (m/z) between 75 and 1200 amu for both
ionisation modes. The data were collected and processed using Xcalibur 2.1.0 software (Thermo Fisher
Scientific, Bremen, Germany).
2.8. Data Extraction and Statistical Analysis
The data were extracted using MZMatch software (SourceForge, La Jolla, CA, USA), http://
mzmatch.sourceforge.net/). A macro-enabled Excel Ideom file was used to filter, compare and identify
the metabolites (http://mzmatch.sourceforge.net/ideom.php). The metabolite lists obtained from
these searches were then carefully evaluated manually by considering the quality of their peaks and
the metabolites were matched with the retention times of authentic standards mixtures run in the same
sequences. Library searches were also used for identification and carried out against accurate mass
data of the metabolites in the Human Metabolome Data Base, KEGG (Kyoto Encyclopedia of Genes
and Genomes), and lipid maps. All metabolites were within 3 ppm of their exact masses. Univariate
comparisons were performed using Microsoft Excel and paired t-tests between treated and control
cells and differences were considered significant at p < 0.05. SIMCA-P software v.14.0 (Umetrics, Umea,
Sweden) was used for multivariate analysis of the metabolite data by fitting PCA-X and OPLS-DA.
3. Results
3.1. BV Fractionation and Isolation of Melittin
A crude BV sample was fractionated by MPLC into three major fractions (F-1, F-2 and F-3).
As previously described [49], F-1 and F-2 were determined to contain mixed components, while F-3
was determined to contain essentially a single component, melittin (Figure S1).
3.2. Cytotoxicity of Melittin against Normal and PMA-Differentiated THP-1 Cells
Cytotoxicity assays were used to test the melittin isolated from BV. The studies were performed
on THP-1 cell lines before and after differentiation with PMA to evaluate the differences in cell
lysis due to melittin (Figure 1). Normal THP-1 cells were slightly more sensitive to melittin than
the differentiated cells, according to their respective IC50 values of 3.14 and 3.3 µg/mL. Figure S2
shows a micrograph of the cells before and after PMA differentiation for 48 h. The monocyte-derived
macrophages became adherent and showed a much greater increase in their cytoplasmic volume when
compared to the untreated control cells [51]. In both cases, dose–response relationships were clearly
observed. The cytokine production was analysed by ELISA following melittin administration at 0.5
and 1 µg/mL doses, whereas melittin was added at 1 µg/mL for the metabolomics study. The cells
showed >90% viability at these melittin doses.
Vaccines 2018, 6, 72 7 of 21
-3.5 -3.0 -2.5 -2.0 -1.5 -1.0 -0.5
0
20
40
60
80
100
IC50 = 3.14 Pg/mL
A)              Effect of Melittin on THP-1 cells
Log concentration (mg/mL)
%
 C
o
n
tr
o
l
B)     Effect of melittin on PMA-differentiated THP-1 cells
-3.5 -3.0 -2.5 -2.0 -1.5 -1.0 -0.5
0
20
40
60
80
100
IC50 = 3.3 Pg/mL
Log concentration (mg/mL)
%
 C
o
n
tr
o
l
΅ȱ¢
΅ȱ ȱ 

΅ȱȱ ȱ
D
D
΅ȱǻ ΅Ǽȱ
ŗΆȱ¢
ŗΆȱ¢ȱǻȱřǼȱȱ
Figure 1. Cytotoxic effect of melittin on THP-1 cells (A) and phorbol 12-myristate 13-acetate
(PMA)-differentiated THP-1 cells (B). The observed effect was determined following administration of
varying doses of melittin. Melittin was cytotoxic to normal THP-1 and PMA-treated cells, with IC50
values of 3.14 and 3.3 µg/mL, respectively. The data represent the mean ± SD (n = 3).
3.3. Effect of Melittin on the Production of Pro-Inflammatory TNF-α Cytokine
As shown in Figure 2, the concentrations of pro-inflammatory TNF-α in THP-1 derived
macrophages were a slight to negligible effect by the combination treatments (LPS + melittin) when
compared to the LPS positive control. The effects in cytokine production in response to LPS + melittin
were not statistically significant (p > 0.05) from the LPS alone (Table S1); however, they were significant
(p < 0.05) from the negative control cells. Two concentrations of melittin were assessed to examine dose
dependency. Samples not treated with LPS showed a background level release of cytokine. The lack of
effect of melittin on TNF-α production in LPS-stimulated macrophages was previously observed [52].
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Figure 2. Effect of melittin on the production of tumour necrosis factor-α (TNF-α) cytokines in the
presence and absence of LPS on PMA-differentiated THP-1 cells. All six treatments were significantly
different from the negative control (n = 3). C: control; Mel: melittin; LPS: lipopolysaccharides;
*: Significant (p < 0.05).
3.4. Effect of Melittin on the Production of Pro-Inflammatory IL-1β Cytokines
A clear increase was noted in the release of the pro-inflammatory IL-1β cytokine (Figure 3) in
response to the combination of melittin and LPS when compared with LPS alone. This synergistic effect
was statistically significant (p < 0.05) for melittin combinations in comparison with cells treated with
LPS alone at 0.5 and 1 µg/mL when melittin was used at 1 µg/mL (Table S2). In contrast to TNF-α,
secretion of LPS-induced IL-1βwas induced dose-dependently in the THP-1-derived macrophages
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in response to melittin treatment. The maximum release of IL-1β was observed after the combined
treatment with 1 µg/mL LPS and melittin. The release of IL-1β was also induced significantly by
melittin alone when compared with the negative control cells [52].
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ŗΆ ŗΆFigure 3. Effect of melittin on the production of Interleukin-1β (IL-1β) cytokines by PMA-differentiated
THP-1 cells in the presence and absence of LPS. Cells treated with all four combination treatments
showed significantly higher release when compared with negative control cells (n = 3). C: control; Mel:
melittin; LPS: lipopolysaccharides; *: Significant (p < 0.05).
3.5. Effect of Melittin on the Production of Pro-Inflammatory Il-6 Cytokines
In agreement with the observed increase in the release of the pro-inflammatory cytokines above,
IL-6 also showed an increase in production in response to treatment with a combination of melittin
and LPS when compared to LPS alone. The effect was statistically significant (p < 0.05) for melittin
and LPS combinations when compared with negative control cells and also with 1 µg/mL LPS alone
(Table S3). Melittin effects were observed at a final concentration of 0.5 µg/mL, whereas effects were
noted for two different doses of LPS (0.5 and 1 µg/mL). Maximum synergism was observed at a final
concentration of 1 µg/mL and 0.5 µg/mL for LPS and melittin, respectively. Melittin alone had no
effect on the level of release of this cytokine or the release was undetectable (Figure 4).
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Figure 4. Effect of melittin on the production of IL-6 cytokine in the presence and absence of LPS on
PMA-differentiated THP-1 cells. Melittin was tested at a 0.5 µg/mL final concentration in combination
with LPS (0.5 and 1 µg/mL) (n = 3). C: control; Mel: melittin; LPS: lipopolysaccharide; *: Significant
(p < 0.05) compared to negative control cells.
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3.6. Effect of Melittin on the Production of Anti-Inflammatory Il-10 Cytokines
The production of anti-inflammatory Il-10 was assessed using 0.5 µg/mL melittin. Interestingly,
the release of this anti-inflammatory cytokine was decreased by the combination of melittin and LPS
(0.5 and 1 µg/mL) when compared with LPS alone. However, the results of the combination treatments
did not reach statistical significance. In addition, no effect was observed for cells treated with melittin
alone when compared with the negative control cells (Figure 5).
Effect of melittin on IL-10 production in
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Figure 5. Effect of melittin on the production of IL-10 cytokine in the presence and absence of LPS on
PMA-differentiated THP-1 cells. Melittin was tested at a 0.5 µg/mL final concentration in combination
with LPS (0.5 and 1 µg/mL) (n = 3). C: control; Mel: melittin; LPS: lipopolysaccharide; *: Significant
(p < 0.05).
3.7. Effect of Melittin on the Cell Metabolome
Understanding how the metabolic response in monocyte-derived macrophages is activated
by different stimuli has important clinical ramifications. The aim of the metabolomic profiling of
PMA-differentiated THP-1 cells following melittin, LPS, and combination treatments was to identify
the mechanism of action of melittin on macrophage cells and to try to understand its synergism with
LPS in cytokine production. Figure 6A shows a clustering of quality control samples (P 1–4) in the
middle of the plot, obtained using principal component analysis (PCA) of all the polar metabolites
detected by analysis on the ZIC-pHILIC column. This finding validates the analysis and indicates
good instrument stability and precision during the run. A clear separation was noted between the
treatment and control groups using an OPLS-DA model (Figure 6B), which would suggest a different
mechanism of action for the combination treatment (melittin + LPS) than for LPS or melittin alone.
Vaccines 2018, 6, 72 10 of 21
Ȯ
 
Ȯ
Figure 6. (A) PCA-X vs. (B) OPLS-DA score plots of THP-1 cells. The figures show a clear separation
between control, pooled, and treatment groups (LPS, melittin, and LPS + melittin) based on 955 polar
metabolites separated on a ZIC-pHILIC column (n = 6). PCA score plot (A) has R2X = 0.668, Q2 = 0.559.
OPLS-DA score plot (B) has R2X = 0.744, R2Y = 0.99, Q2 = 0.903. (C: control; Mel: melittin; LPS:
lipopolysaccharide; Mel + LPS: melittin and LPS combination treatments; P = pooled samples). PCA:
principal component analysis.
Based on previous observations on the effect of melittin on cell lipids [24], other data sets were
obtained using a reversed phase (RP) column (ACE C4 column) to characterise the changes in non-polar
metabolites. As shown in Figure 7, the separation between groups was clearer for lipophilic metabolites
than for polar metabolites using an OPLS-DA model. Clustering of pooled (P 1–3) samples in the PCA
model showed the validity of the analysis and the stability of the instrument throughout the run.
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Figure 7. (A) PCA-X vs. (B) OPLS-DA score plots of THP-1 cells. The figures show a clear separation
between control, pooled and treatment groups (LPS, melittin and LPS + melittin) based on 128
significant non-polar metabolites separated on an ACE C4 column (n = 4). PCA score plot (A)
has R2X = 0.867, Q2 = 0.753. OPLS-DA score plot (B) has R2X = 0.896, R2Y = 0.978, Q2 = 0.895.
(C: control; Mel: melittin; LPS: lipopolysaccharide; Mel + LPS: melittin and LPS combination treatments;
P = pooled samples).
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Univariate comparisons of the changes in metabolites in each group are shown in Table 1 and
demonstrate clear differences in the metabolite levels between cells treated with LPS and melittin alone,
thereby confirming distinct metabolic profiles for the combination treatments (melittin + LPS). Several
metabolomics pathways were significantly altered (particularly glycolysis, TCA cycle, OXPHOS,
arginine and proline metabolism, and nucleotide metabolism). Clearly significant increases were noted
in the levels of fatty acids, whereas glycerophospholipid levels were decreased by melittin regardless
of the presence or absence of LPS.
Table 1. Significantly changed metabolites within THP-1 cells treated with lipopolysaccharide (LPS),
melittin, and melittin + LPS in comparison with untreated controls. The results contain the majority of
affected metabolites. (0.5 µg/mL LPS; 1 µg/mL melittin).
Mass Rt Putative Metabolite
LPS Mel Mel + LPS
Ratio p Value Ratio p Value Ratio p Value
Arginine and proline metabolism
175.096 15.25 L-Citrulline * 1.825 0.048 7.482 0.001 8.657 0.001
174.112 26.50 L-Arginine * 0.255 <0.001 1.111 ns 0.916 ns
240.122 15.55 Homocarnosine 0.640 0.005 1.570 0.002 1.481 0.001
145.085 14.52 4-Guanidinobutanoate 1.122 0.014 0.792 <0.001 1.611 <0.001
246.133 13.55 N2-(D-1-Carboxyethyl)-L-arginine 0.295 <0.001 0.951 ns 1.544 <0.001
113.059 9.30 Creatinine 0.288 <0.001 1.045 ns 1.234 ns
129.043 13.62 Oxoproline 0.135 <0.001 0.192 <0.001 0.182 <0.001
290.123 15.83 N-(L-Arginino) succinate 0.562 <0.001 1.367 0.006 0.832 0.040
132.090 23.04 L-Ornithine * 0.387 <0.001 1.051 ns 1.177 0.004
147.053 13.45 L-Glutamate * 0.661 <0.001 0.917 ns 0.855 0.026
398.137 16.01 S-Adenosyl-L-methionine 0.768 ns 5.717 <0.001 4.267 <0.001
115.063 12.14 L-Proline * 0.439 <0.001 0.909 ns 1.103 ns
Glycolysis/TCA cycle
339.996 17.18 D-Fructose 1,6-bisphosphate * 1.397 ns 0.544 <0.001 0.671 0.009
260.030 15.02 D-Fructose 6-phosphate * 1.210 ns 1.620 <0.001 1.590 <0.001
260.020 15.94 D-Glucose 6-sulfate 2.193 0.000 1.359 ns 1.190 0.018
260.030 15.83 D-Glucose 1-phosphate * 1.366 0.004 2.264 <0.001 1.909 <0.001
809.125 12.25 Acetyl-CoA 0.713 0.027 0.946 ns 0.792 0.028
185.993 15.94 3-Phospho-D-glycerate 0.753 0.001 0.610 <0.001 0.501 <0.001
169.998 15.10 Glycerone phosphate 0.381 <0.001 0.315 <0.001 0.249 <0.001
192.027 17.28 Citrate * 0.318 <0.001 1.089 ns 1.297 0.001
192.027 18.47 Isocitrate * 0.489 <0.001 0.580 <0.001 0.466 <0.001
116.011 14.82 Fumarate * 0.751 0.013 0.891 ns 0.677 0.001
665.125 13.23 NADH * 0.324 <0.001 0.492 <0.001 0.584 <0.001
663.109 14.17 NAD+ * 0.482 <0.001 0.923 ns 0.671 <0.001
OXPHOS/Pentose phosphate pathway
506.996 15.76 ATP * 0.751 0.006 0.987 ns 0.585 <0.001
427.030 14.31 ADP * 0.534 <0.001 0.812 0.012 0.640 <0.001
258.014 16.69 D-Glucono-1,5-lactone 6-phosphate 1.214 ns 1.207 ns 1.407 0.026
290.041 15.23 D-Sedoheptulose 7-phosphate 1.831 <0.001 1.181 0.002 1.489 <0.001
230.019 14.60 D-Ribulose 5-phosphate 0.932 ns 0.579 0.000 0.713 0.005
370.007 17.42 D-Sedoheptulose 1,7-bisphosphate 1.725 0.002 0.758 ns 1.065 ns
745.091 16.74 NADPH * 1.845 0.049 1.521 ns 0.508 0.048
743.075 16.51 NADP+ 0.693 0.030 0.764 0.031 0.820 0.047
Purine metabolism
151.049 11.82 Guanine * 1.300 ns 0.632 0.010 1.707 0.001
283.092 12.93 Guanosine 1.310 ns 0.619 0.015 2.185 0.001
348.047 14.40 IMP * 2.093 ns 2.305 0.021 1.727 ns
268.081 10.32 Inosine * 4.079 <0.001 1.852 0.001 6.051 <0.001
168.028 11.38 Urate * 0.168 <0.001 1.372 0.001 1.838 <0.001
136.039 9.74 Hypoxanthine * 7.345 <0.001 4.852 <0.001 33.584 <0.001
152.034 10.46 Xanthine 0.283 <0.001 1.109 0.043 1.264 0.003
284.076 9.72 Xanthosine 0.270 <0.001 1.019 ns 1.259 0.015
135.054 9.22 Adenine 1.246 ns 2.237 0.009 1.649 ns
347.063 12.62 AMP * 0.538 0.002 0.873 ns 0.339 <0.001
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Mass Rt Putative Metabolite
LPS Mel Mel + LPS
Ratio p Value Ratio p Value Ratio p Value
Pyrimidine metabolism
403.018 16.15 CDP * 0.584 <0.001 0.690 0.001 0.650 0.002
111.043 11.38 Cytosine 0.684 ns 2.434 ns 3.660 0.021
482.985 17.60 CTP * 0.659 0.001 0.719 0.001 0.463 <0.001
243.086 11.36 Cytidine * 0.528 <0.001 2.375 <0.001 3.628 <0.001
483.969 17.02 UTP * 0.617 <0.001 0.685 <0.001 0.437 <0.001
324.036 15.17 UMP * 0.721 0.011 0.630 <0.001 0.589 <0.001
404.003 15.58 UDP * 0.422 <0.001 0.666 0.001 0.534 <0.001
580.035 17.95 UDP-glucuronate 0.604 <0.001 0.560 <0.001 0.495 <0.001
566.055 16.00 UDP-glucose 0.637 0.000 0.555 0.000 0.457 <0.001
605.077 17.17 GDP-mannose 1.812 <0.001 1.996 <0.001 1.532 <0.001
Fatty acids and metabolites C4
306.256 12.45 Eicosatrienoic acid * 1.650 0.004 1.983 ns 1.977 <0.001
328.240 18.27 Docosahexaenoic acid * 0.346 ns 6.658 0.002 5.846 0.002
318.219 4.10 Leukotriene A4 or isomer 1.115 ns 1.469 ns 2.183 0.002
310.287 17.73 Eicosenoic acid * 1.328 ns 0.477 ns 0.313 0.009
356.256 14.78 Prostaglandin F1alpha or isomer 0.276 0.007 0.479 0.024 0.482 0.048
336.230 4.55 Prostaglandin B1 or isomer 1.004 ns 1.432 ns 2.125 <0.001
402.225 4.00
5S-HETE di-endoperoxide or
isomer
1.709 ns 0.850 ns 0.650 0.007
282.256 20.06 Oleic acid * 1.239 0.036 9.007 <0.001 8.089 <0.001
256.240 7.84 Hexadecanoic acid isomer 1.397 0.005 7.235 <0.001 13.602 0.004
338.319 24.61 Docosenoic acid * 1.246 0.005 2.740 <0.001 2.941 <0.001
268.240 11.26 Heptadecenoic acid 1.362 0.013 1.782 <0.001 1.211 ns
366.350 26.59 Tetracosenoic acid * 1.354 0.038 2.665 <0.001 2.800 <0.001
304.240 18.36 Eeicosatetraenoic acid * 1.049 ns 46.370 <0.001 42.444 <0.001
332.272 20.30 Docosatetraenoic acid 0.929 ns 25.404 <0.001 21.474 <0.001
242.225 17.97 Pentadecanoic acid * 0.967 ns 1.787 <0.001 1.758 <0.001
334.287 21.82 Docosatrienoic acid * 0.776 ns 8.679 0.001 7.684 0.001
226.193 15.25 Tetradecenoic acid 0.890 ns 3.570 0.002 3.367 0.003
270.256 12.86 Heptadecanoic acid 0.874 ns 4.801 0.010 1.854 0.009
278.225 17.08 Linolenic acid * 0.789 0.029 3.716 <0.001 2.861 <0.001
280.240 18.38 Linoleate * 1.105 ns 9.760 <0.001 8.943 <0.001
Glycerophospholipids C4
721.467 12.69 PC 32:6 0.672 ns 0.214 0.016 0.217 0.023
832.654 30.65 PG 41:0 ether 0.665 0.028 0.623 0.019 0.402 0.003
738.448 12.65 PG34:6 0.949 ns 0.357 0.020 0.308 0.015
484.280 13.33 Lyso PG 16:0 1.589 ns 0.449 0.034 0.283 0.013
800.449 12.56 PI 32:5 0.885 ns 0.365 0.009 0.329 0.005
584.333 13.28 Lyso PI 18:0 Ether 0.941 ns 0.558 0.020 0.499 0.004
858.526 13.47 PI 36:4 1.841 ns 0.441 0.025 0.316 0.027
814.501 13.55 PI 34:4 ether 2.088 ns 0.486 0.025 0.317 0.019
785.521 32.15 PS 36:3 0.789 0.008 0.782 0.005 0.779 0.007
517.244 12.56 Lyso PS 18:4 1.184 ns 2.645 <0.001 1.659 0.022
833.520 22.16 PS 40:7 1.118 ns 0.439 0.004 0.470 0.009
777.457 13.50 PS 36:7 0.970 ns 0.432 0.023 0.371 0.010
Miscellaneous
131.058 13.88 N-Acetyl-beta-alanine 2.017 0.004 4.879 0.001 5.950 0.001
217.143 15.88 beta-Alanyl-L-lysine 1.543 0.041 3.816 <0.001 1.705 0.021
182.079 13.10 D-Sorbitol * 0.325 <0.001 2.226 <0.001 4.443 <0.001
180.064 12.66 D-Mannose * 0.712 <0.001 1.538 <0.001 1.744 <0.001
180.064 14.19 D-Galactose 1.326 ns 3.785 0.001 4.184 0.001
221.090 11.16 N-Acetyl-D-glucosamine * 0.464 <0.001 0.953 ns 0.806 0.008
146.069 14.34 L-Glutamine * 0.370 <0.001 1.085 ns 1.322 0.002
129.043 10.45 5-Oxoproline * 2.424 0.018 0.897 ns 1.192 ns
220.085 8.96 5-Hydroxy-L-tryptophan * 7.211 <0.001 1.131 0.010 4.305 <0.001
204.090 11.14 L-Tryptophan * 0.190 <0.001 1.189 ns 1.311 0.046
181.074 12.34 L-Tyrosine * 0.309 <0.001 1.050 ns 1.265 0.042
131.095 10.77 L-Leucine * 0.217 0.008 1.038 ns 1.226 0.048
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Table 1. Cont.
Mass Rt Putative Metabolite
LPS Mel Mel + LPS
Ratio p Value Ratio p Value Ratio p Value
117.079 11.94 L-Valine * 1.615 0.001 6.492 0.000 2.822 0.002
612.152 16.40 Glutathione disulfide 0.652 <0.001 1.186 0.047 1.109 ns
142.074 13.04 Ectoine * 1.164 ns 0.553 <0.001 0.196 <0.001
131.069 13.99 Creatine * 0.547 <0.001 0.615 <0.001 0.439 ns
103.100 20.48 Choline * 0.444 <0.001 3.571 <0.001 2.827 <0.001
105.043 15.44 L-Serine * 1.518 <0.001 1.737 <0.001 1.707 <0.001
121.020 15.41 L-Cysteine * 0.581 <0.001 2.182 <0.001 4.862 <0.001
155.070 15.87 L-Histidine * 1.088 ns 2.089 <0.001 3.122 <0.001
161.105 12.59 L-Carnitine * 0.608 <0.001 0.822 0.008 0.744 0.002
238.230 12.66 2-trans-Hexadecenal C4 0.795 ns 16.865 0.000 12.016 0.000
Rt: Retention time (min); LPS: Lipopolysaccharides; Mel: melittin; Mel + LPS: melittin + LPS combination treatment;
C4: Detected by ACE C4 column; *: Matches the analytical standard retention time; ns: Non-significant.
The plot shows heat map of the top 30 significant metabolites from Table 1. The clearest effect
in the heat map was that the similarity in the effect between LPS alone and Mel + LPS. Most of the
metabolites were decreased with LPS treatment. Some metabolites are more abundant in combination
treatment of Mel + LPS as compared to LPS alone, such as citrulline, hypoxanthine, and inosine
(Figure 8).
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Figure 8. Heat map showing the top 30 significant putative metabolites among control (C), LPS,
and melittin + LPS (Mel + LPS) using one-way ANOVA. The data are displayed on a log2 scale.
The differences in colour shades represent intensities of the metabolites vs. sample observations.
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4. Discussion
The efficacy of vaccines can be improved by the safe use of adjuvant substances, which are
substances that modulate and enhance the immunogenicity of a vaccine antigen [53]. The aim
of the present study was to investigate the potential usefulness of the BV compound, melittin as
a natural vaccine adjuvant to stimulate the innate and adaptive immune systems. The research
strategy was to characterise the ability of melittin to modify cytokine production in LPS-stimulated
PMA-differentiated THP-1 cells. The effects of melittin, in combination with LPS, on the metabolic
profiles of monocyte-derived macrophages were also evaluated to determine if metabolomic profiling
of immune-modulating agents can provide a more in-depth understanding of the mechanisms and
pathways of cytokine secretion.
The cytotoxicity assays showed that the THP-1 monocytes were no longer viable when exposed to
6.25 µg/mL melittin, while the PMA-differentiated cells retained 18% cell viability. No significant cell
lysis was observed below 1.56 µg/mL for the normal THP-1 cells, which confirmed a greater melittin
sensitivity of the cells with a lower IC50 value, when compared to cells differentiated into macrophages.
The pro-inflammatory IL-1β showed themost enhanced release in response tomelittin and the response
was dose-dependent and also its release was significantly higher than LPS alone when 1 µg/mL of
melittin was used in combination with LPS. A significant enhancement was also observed for IL-6
cytokine comparing with LPS alone with 0.5 µg/mL of melittin, but only a slight non-significant
enhancement was observed for TNF-α which reflects the findings of an earlier study. Interestingly, the
production of the anti-inflammatory IL-10 was decreased by melittin in the combination treatment
with LPS, which might support the use of melittin as a pro-inflammatory enhancer. These results
support our previous findings on the effect of melittin on cytokine secretion by the U937 cell line [34],
using the same experimental design.
IL-1β, a prototypic pro-inflammatory cytokine, has an essential role in immune responses and
possesses adjuvant activity [54,55]. The production of IL-1β and IL-18 is increased by aluminium
hydroxide, a routinely used adjuvant, which is believed to activate caspase-1 [56]. Several studies
have reported that melittin has adjuvant activity that may arise by a different mechanism, perhaps
by enhancing the absorption properties of vaccines when they are administered nasally [36]. Melittin
can serve as a mucosal adjuvant for antigens administered via the nasal route as it enhances antibody
titres in a dose-dependent manner when conjugated with tetanus and diphtheria toxoids [37].
Another study has shown that melittin induces the synthesis of TNF-α and IL-1β in a time-
and dose-dependent manner through activation of phospholipase A2 (PLA2) [57,58]. A deeper
understanding of the immune-stimulatory mechanism of adjuvants is a prerequisite for the design of
more sophisticated vaccines.
The comparisons of control cells versus LPS-, melittin-, and LPS + melittin-treated cells revealed
large numbers of metabolite differences. Overall, a synergistic effect was clearly evident in terms of the
ratios of some of the inflammatory response metabolites when comparing the combination treatment
with LPS alone (Table 1). The LPS-stimulated macrophages showed upregulation of the arginine
metabolism, which resulted in the increased production of citrulline, which is an indicator of increased
NO production, a hallmark of inflammation [59]. The levels of citrulline were increased by melittin
alone and there was a clear synergic effect in combination with LPS. The levels of arginine, a precursor
of NO and citrulline, and the N-(L-arginino)-succinate level were decreased in response to LPS alone
and melittin with LPS treatments, but the N-(L-arginino)-succinate was not depleted when melittin
alone was used. This might be due to the increased expression of argininosuccinate synthase (Ass1)
and argininosuccinate lyase (Asl) [60]. These two enzymes are used to maintain levels of arginine with
arginine succinate being exported from the cells and then retrieved again and converted to arginine
when the arginine level is depleted in order to optimize the production of NO [60]. NO nitrosylation
inhibits the components of the electron transport chain, thereby leading to OXPHOS inhibition through
the suppression of complex II [61].
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Several studies have shown an increase in aerobic glycolysis and a decrease in the TCA cycle
and electron transport chain in macrophages due to increased release of NO [62,63]. Decreases in
TCA cycle activity will lead to increases in the production of mitochondrial reactive oxygen species
(ROS) and subsequent cytokine secretion [13,61]. The subsequent decrease in ATP production (Table 1)
then leads to reprogramming of the cell metabolites and switching to glycolysis after the decline in
OXPHOS. This serves as a survival response to maintain the level of ATP in the cells [64]. Despite
the small effect seen on acetyl-CoA, the LPS and combination treatments caused decreases of ~30%
and ~20%, respectively, which confirmed the inhibition of the TCA cycle and diversion of pyruvate to
lactate instead of acetyl-CoA [4,10]. At the same time, shunting glucose through the pentose phosphate
pathway (PPP) generates nicotinamide adenine dinucleotide phosphate (NADPH), which showed
a significantly increased level in response to LPS treatment alone and is required for oxidative reactions,
glutathione recycling, NO production, and ROS production [1]. Melittin was reported to increase the
production of ROS and to induce apoptosis in TNF-related apoptosis-inducing ligand (TRAIL)-resistant
HepG2 cells and the fall in NADPH with the melittin treatments may indicate increased consumption,
this would fit with the higher levels of citrulline in the melittin treatments [65].
An elevation in PPP metabolites can boost the production of purines and pyrimidines for
biosynthesis in activated cells [66]. Knockdown of the carbohydrate kinase-like protein (CARKL),
a sedoheptulose kinase that catalyses the production of D-sedoheptulose 7-phosphate (S7P),
was reported after LPS treatment and could potentiate the production of cytokines and M1
macrophage polarisation [11,67]. An increased flow of glycolytic intermediate metabolites into the
oxidative arm of the PPP generated more NADPH from the conversion of glucose-6-phosphate
to ribulose-5-phosphate (Ru5P). When the cellular need for NADPH exceeded that required for
biosynthesis of nucleotides, Ru5P passed into the redox arm of PPP to increase the flux to glycolysis
by generating fructose-6-phosphate (F6P) and glucose-6-phosphate (G6P). Thus, F6P was strongly
elevated in response to the melittin alone and melittin and LPS combination treatment. S7P, a key
control metabolite, was particularly elevated. In the same study, metabolomics analysis to revealed the
metabolites linked to CARKL expression demonstrated that ribose-5-phosphate, xyulose-5-phosphate,
S7P, glyceraldehyde-3-phosphate (G3P), G6P, and F6P were elevated concomitantly with a marked
depletion of some TCA metabolites (such as malate and fumarate) and decreases in NADH levels [11].
These findings are similar to the current metabolomics results of some metabolites including fumarate,
Ru5P, S7P and F6P (Table 1).
In the present study, a strong effect on cellular purine and pyrimidine metabolism was observed
for the combination treatment. Guanine, guanosine, inosine, urate, hypoxanthine, xanthine, xanthosine,
adenine, AMP, cytosine, cytidine, CTP, UTP, and UMP all showed a clear synergistic effect for the
combination treatment when compared with LPS alone (Table 1). The effect of melittin in lowering
UMP, UDP, UTP and UDP–glucose is of interest since UDP–sugar conjugates are involved in protein
N-glycosylation and are upregulated in M2 macrophages [59]. It has been proposed that melittin can
reduce the number of M2-like macrophages in an increasing cell population, producing a relative
increase in M1 macrophages [52]. A reduction in the population of M2 cells has also been linked
to a lowering of glutamine catabolism, which was observed in the current case for the melittin LPS
combination. These findings resemble those of a previous study that showed elevated levels of xanthine,
hypoxanthine, inosine, guanine, and guanosine in gingival crevicular fluid inflammation sites when
compared with a healthy human oral cavity [68]. Higher levels of hypoxanthine were also observed in
response to macrophage activation by LPS in the RAW 264.7 cell line [41]. The hyperactivity of purine
degradation and the increase in hypoxanthine (33-fold) and inosine (6-fold) in themelittin + LPS-treated
cells represent potential biomarkers for inflammation, as these result in greater production of ROS
through xanthine oxidase, thereby causing cellular oxidative stress [68]. These results support previous
findings in patients with inflammatory arthritis, where the levels of hypoxanthine, xanthine, and urate
were higher in synovial fluid than in plasma, and hypoxanthine concentrations were significantly
higher in the plasma from patients than from the control group [69]. Metabolic profiling of rheumatoid
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arthritis patients also indicated a significant increase in hypoxanthine levels when compared to healthy
controls [70]. Overall, the results in the present study indicated a significant change in amino acid and
nucleotide biosynthesis upon activation by the combination of LPS and melittin. Cell reprogramming
was clearly observed by the combination treatment, which supports the use of melittin to stimulate
cellular immune responses and its potential use as an immune adjuvant agent.
Metabolic profiling of lipophilic metabolites separated using a reversed phase column revealed
significant changes in fatty acids of interest. LPS caused a slight increase in fatty acid synthesis by
increasing the expression of the mitochondrial citrate carrier [71]. This would cause an accumulation
of citrate in the cell cytoplasm through exchange with malate, and the citrate is then converted to
oxaloacetate and acetyl-CoA, using ATP. Acetyl-CoA is then converted to malonyl-CoA, which is used
for fatty acid synthesis [4,72]. LPS treatment was also found to inhibit the activity of the AMP-kinase in
macrophages, causing a decrease in β-oxidation of fatty acids to produce inflammatory mediators [20].
Melittin, alone or in combination with LPS, caused a significant increase in the level of several fatty
acids. These increases would explain the ability of melittin to cause disruption of the cell membrane,
as confirmed by several previous findings [25,73]. Arachidonic acid (i.e., eicosatetraenoic acid) release
from the cells was significantly increased by 46-fold and 42-fold by treatment with melittin and melittin
+ LPS, respectively (Table 1 and Figure S15). Several studies have shown that melittin activates the
arachidonic acid signalling pathway in many cell lines, including PC12 and L1210 [74,75], and in
neurons [76]. The mechanism of arachidonic acid production is argued to occur through multiple
pathways to regulate cellular activity. One possibility is that it works through the stimulation of
phospholipase A2; however, this effect was reported to lack selectivity for phospholipase A2 and fatty
acid release [74]. The production of linoleic acid and linolenic acid, a precursor of arachidonic acid,
was significantly increased in response to melittin, which would support the lytic activity of melittin
on the cell membrane and its ability to penetrate phospholipid bilayers [21].
Arachidonic acid has a considerable importance in the immune system and in the promotion
of inflammation. It can be metabolised via enzymatic reactions, including cyclooxygenase (COX),
lipoxygenase, cytochrome p450 (CYP 450), and the enzymes of the anandamide pathways to
create 20-carbon molecules (eicosanoids) such as prostaglandin (PG) and other signalling molecules.
Eicosanoids are produced mainly following stimulation of the inflammatory process and in innate
immunity regulation [77,78]. Melittin was indicated to induce mRNA levels of COX-2 and IL-8 in
fibroblast-like synoviocytes [21]. The apparent strong involvement of the arachidonic acid pathway
in the production of pro-inflammatory mediators supports the potential use of melittin for immune
activation and as an immune-adjuvant vaccine agent. In addition to the synergistic effect of melittin to
LPS in most of the amino acids and nucleotides, its effect on cells lipids was very marked, suggesting
membrane re-modelling of macrophages cells upon activation by melittin with a particular selectivity
for lipids carrying long-chain polyunsaturated fatty acids.
5. Conclusions
In conclusion, PMA-differentiated THP-1 cells showed a significant enhancement in the secretion
of IL-1β and IL-6 cytokines in response to treatment with a combination of melittin and LPS when
compared to LPS alone when a 1 µg/mL concentration was used. Melittin combined with LPS also
produced a decrease in the level of the anti-inflammatory IL-10 cytokines. However, there was little
effect of melittin on the level of TNF-α, which mirrors what was observed previously. In addition,
this study provides an outline of the metabolites associated with cytokine production and immune
system activation by LPS, melittin, or LPS + melittin. The clearest effects of the combination of LPS and
melittin treatment were on glycolysis, the TCA cycle, OXPHOS, and purine, pyrimidine, and fatty acid
metabolism. The most marked effects were on the levels of polyunsaturated fatty acid and associated
with this a reduction in the levels of some long-chain highly unsaturated phospholipids. Exposure
to the combination treatment resulted in marked elevation of most fatty acids, and arachidonic acid
in particular, suggesting different metabolic responses to LPS, melittin, and the melittin and LPS
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combination. The effect of melittin in lowering UTP levels and UDP-glucose fits with a previous
report that UDP–sugar conjugates may be important for conferring M2-like properties to macrophages.
To the authors’ knowledge, this is the first time that melittin has been shown to work as an immune
adjuvant based on results from metabolic profiling of monocyte-derived macrophages. Our results
emphasise that the use of melittin in combination with LPS could result in improved therapy for
vaccine immunisation. Certainly, melittin shows promise as a potential vaccine adjuvant.
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